Connect with us

Hi, what are you looking for?

Your Retire Invest


“Voting Results In: BriaCell Therapeutics Corp. Makes History!”

Briacell Therapeutics Corp. (“Briacell” or the “Company”) (TSXV: BCT) is pleased to announce the voting results from its special meeting of shareholders held on April 28, 2021 (the “Meeting”).

At the Meeting, shareholders voted in favour of the special resolution approving the previously announced plan of arrangement (the “Arrangement”) involving the Company, its wholly-owned subsidiary, Briacell Therapeutics USA, Inc. (“Briacell USA”), and its shareholders.

The Arrangement was approved by 99.99% of the votes cast by shareholders present in person or represented by proxy at the Meeting. The Arrangement was also approved by 99.99% of the votes cast by shareholders present in person or represented by proxy at the Meeting, excluding the votes cast by shareholders who are related to the Company’s directors and officers.

The Arrangement will result in the Company becoming a wholly-owned subsidiary of Briacell USA and the Company’s shareholders receiving cash consideration of $0.50 per common share of the Company.

The Arrangement is subject to the satisfaction or waiver of certain conditions, including the receipt of all necessary court, regulatory and other third-party approvals. The Company expects to complete the Arrangement in the second quarter of 2021.

Briacell is a clinical-stage biotechnology company focused on the development of novel therapies for the treatment of cancer and other diseases. The Company’s lead product candidate, BCT-001, is a novel small molecule inhibitor of the PI3K/AKT/mTOR pathway, which is a key regulator of cell growth and survival.

The Company is currently conducting a Phase 1/2 clinical trial of BCT-001 in combination with chemotherapy in patients with advanced solid tumors. The Company is also developing BCT-002, a novel small molecule inhibitor of the PI3K/AKT/mTOR pathway, for the treatment of advanced solid tumors.

Briacell is committed to developing innovative therapies that have the potential to improve the lives of patients with cancer and other diseases. The Company is focused on advancing its clinical programs and expanding its pipeline of novel therapies.

We would like to thank our shareholders for their support of the Arrangement. We look forward to completing the Arrangement and continuing to advance our clinical programs and pipeline of novel therapies.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Editor's Pick

Controversy ensued recently when a vocal group within the Republican party (in the United States) began to make the argument that the Speaker position,...


In an effort to promote stronger loyalty among customers, Delta Air Lines has recently announced changes that will make it more difficult to earn...

Top News

Intensified aerial strikes in and around the Hamas-controlled Gaza Strip have been met with retaliatory releases of Israeli hostages by the militant organization. On...


Citigroup, one of the world’s leading multinational investment banks and a behemoth in the financial services sector, recently unveiled plans to trigger a significant...

Disclaimer:, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 YourRetireInvest. All Rights Reserved.